Stock Price
3.09
Daily Change
-0.13 -4.04%
Monthly
12.36%
Yearly
-29.29%
Q2 Forecast
3.03

MannKind reported $251.16M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Adma Biologics USD 511.17M 44.66M Mar/2026
BioCryst Pharmaceuticals USD 373.62M 30.72M Mar/2026
Eli Lilly USD 54.84B 794M Mar/2026
Halozyme Therapeutics USD 1B 177.83M Mar/2026
Insmed USD 1.61B 181.04M Mar/2026
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
MacroGenics USD 182.52M 37.42M Mar/2026
MannKind USD 251.16M 40.42M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Novavax USD 850.82M 127.46M Mar/2026
Novo Nordisk DKK 25.71B 148.69B Jun/2025
Pfizer USD 42.82B 76M Mar/2026
Sanofi EUR 30.16B 789M Mar/2026
Xencor USD 482.85M 116.97M Mar/2026